진원생명과학, 연결 영업손실 440억…적자 지속

Jinwon Bioscience's continued operating losses and 52.1% capital impairment rate reveal deepening financial distress in Korea's biotech sector. The company's declining revenue combined with mounting cumulative losses raise critical questions about long-term viability and highlight the cash burn crisis facing pre-profitability biotech firms. This case underscores structural challenges in commercializing early-stage biotech ventures in a competitive market.